XML 80 R64.htm IDEA: XBRL DOCUMENT v3.5.0.1
Equity Instruments (Details 2) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Jun. 30, 2015
Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense         $ 1,018,000 $ 500,000
Unrecognized expense at March 31, 2016 $ 1,554,000          
Weighted average remaining years to vest (in years) 2 years 10 months 24 days          
Vyrix Pharmaceuticals Inc [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized expense at March 31, 2016         $ 0  
Weighted average remaining years to vest (in years)         0 years  
Luoxis Diagnostics [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized expense at March 31, 2016         $ 0  
Weighted average remaining years to vest (in years)         0 years  
Stock Options [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense $ 296,000 $ 272,000 $ 547,000 $ 750,000    
Research and Development Expense [Member] | Vyrix Pharmaceuticals Inc [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense         $ 92,000 38,000
Research and Development Expense [Member] | Luoxis Diagnostics [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense         427,000 206,000
Research and Development Expense [Member] | Stock Options [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense 38,000 115,000 63,000 323,000    
General and Administrative Expense [Member] | Vyrix Pharmaceuticals Inc [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense         183,000 104,000
General and Administrative Expense [Member] | Luoxis Diagnostics [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense         $ 316,000 $ 152,000
General and Administrative Expense [Member] | Stock Options [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense $ 258,000 $ 157,000 $ 484,000 $ 427,000